Ascendis Pharma Files 6-K for June 2025
Ticker: ASND · Form: 6-K · Filed: Jun 11, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K on 6/11/25, mostly for S-8 filings.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on June 11, 2025, to report information as a foreign private issuer. The filing is incorporated by reference into several S-8 registration statements, which are used for employee stock plans.
Why It Matters
This filing indicates Ascendis Pharma is providing updated information to the SEC, which is standard for foreign private issuers and may contain details relevant to ongoing business operations or regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative report for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
- 333-228576 (company) — Form S-8 Registration Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it distributes or makes public to its security holders.
What does it mean for this filing to be incorporated by reference into Form S-8 registration statements?
It means that the information contained in this 6-K filing is considered part of the S-8 registration statements, which are typically used by companies to register securities to be offered to employees under employee benefit plans.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 11, 2025.
What is the principal executive office address of Ascendis Pharma A/S?
The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports on Form 20-F or 40-F?
Ascendis Pharma A/S indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 11, 2025 regarding Ascendis Pharma A/S (ASND).